Cellular Operations is led by Alex Alderton and consists of approximately 60 scientists with specialist skills and experience across a number of key technology platforms:
Induced Pluripotent Stem (iPS) Cells
We generate human iPS cells from blood and skin samples and differentiate those pluripotent cells into a range of different cell types. Current protocols include macrophage, cortical and dopaminergic neurons. This work is performed by our Cellular Generation and Phenotyping team.
We have expertise in the derivation and culture of 3D organoid lines from human tissue samples. In particular the team have extensive experience the generation of organoid models from tumours to develop new cellular models for cancer research. This work is performed by our Cellular Generation and Phenotyping team.
We carry out large scale CRISPR-Cas9 screens in a range of different cell lines. These screens allow investigators to study the impact of genetically altering thousands of genes in the genome in a single experiment. This work is performed by our Cellular Generation and Phenotyping team and Gene editing teams.
We use highly efficient methods that take advantage of CRISPR-Cas9 technology to genetically engineer a range of cell types. Current services offered include gene knockouts, SNP introduction, protein tags and vector construction. This work is performed by our Gene editing team
Flow Cytometry and Cell Sorting
Our Flow Cytometry team offer investigators state of art instrumentation and expertise in flow cytometry. The facility is equipped with four high throughput cell analysers and five cell sorters.
The majority of our work involves collaborating with other teams to carry out specific scientific projects. In addition, we also undertake our own R&D to develop tools, establish new platforms and processes and to identify potential efficiency improvements. R&D is carried out by scientists within all of our teams as well as in our dedicated R&D team.
Cellular Generation and Phenotyping
The Cellular Generation and Phenotyping (CGaP) core facility provides central cell biology support to the Sanger Institute, functioning as a contract ...
Cellular and Gene Editing Research
We develop novel genome editing techniques, cellular differentiation and cellular phenotyping systems, especially with respect to high-throughput investigation of gene and ...
Cytometry Core Facility
The Cytometry Core Facility at the Wellcome Trust Sanger Institute is a dedicated scientific service offering investigators with state-of-the-art flow cytometry ...
Cancer Dependency Map
The Cancer Dependency Map integrates the work of multiple experimental and computational research project at the Sanger Institute with the ...
Deciphering Developmental Disorders (DDD)
The aim of the Deciphering Developmental Disorders (DDD) Study is to advance clinical genetic practice for children with developmental disorders by ...
EBiSC - European Bank for induced pluripotent Stem Cells
The European Bank for induced pluripotent Stem Cells (EBiSC) is a large European public-private partnership project supported jointly by the Innovative ...
Human Cancer Models Initiative (HCMI)
The Human Cancer Models Initiative is an international effort to generate, genomically characterise and annotate the next-generation of cancer cell models ...
Related news and blogs
14 Mar 2022
New hope for treatment of infant cancer that has puzzled researchers for decades
Subtle differences detected in immune cell type from which infant leukaemia arises
12 Feb 2021
New COVID-19 saliva testing strategy could translate into easy-to-use home device
The new testing approach would be easier to collect and simpler to process in the laboratory than the current nasal-swab process.